Series C is led by Koch Disruptive Technologies and includes Bristol Myers Squibb, DFJ Growth, Willett Advisors and existing investors Eclipse, Dech...
Under the collaboration, Boostimmune will have access to WuXi XDC's fully integrated, one-stop bioconjugate platform and extensive expertise in industry-le...
The GMP release of its first DS facility in China enhances WuXi Vaccines' capability in providing global partners with comprehensive end-to-end solutions, ...
Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the s...
“Samsung Biologics is fully committed to engaging in sustainable business practices for the positive impact it has on our clients, society, and the w...
The company is pleased to disclose its advancement of up to 12 g or more / L expression of recombinant protein - fully folded / biologically active in ferm...
Under the partnership, Pharmadule Morimatsu will provide modular facilities for the WuXi Biologics Singapore CRDMO Center project. This strategic ...
By using this cutting-edge imaging technology in preclinical studies, Oncodesign Services’ team hopes to gain insights of the predictive effectivenes...
Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was acquired by A...
Report now includes Scope 3 emissions Employee-driven social responsibility takes precedence as driving force for sustainability activities Goal to red...
Charles River Laboratories International, Inc. (NYSE: CRL) and the INADcure Foundation, a nonprofit organization whose mission is to support the developmen...
As the first facility of Samsung Biologics’ second Bio Campus at its headquarters in Songdo, South Korea, Plant 5 is expected to have the shortest co...
- In response to global clients' increasing demand for contract manufacturing services, WuXi Biologics is expanding its capacity for drug substance a...
Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), annou...
© 2024 Biopharma Boardroom. All Rights Reserved.
